Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer.

CONCLUSIONS: Abemaciclib is an effective and well-tolerated treatment for HR-positive, HER2-negative advanced or metastatic breast cancer.
PMID: 30099886 [PubMed - as supplied by publisher]

Source: The Annals of Pharmacotherapy - August 13, 2018 Category: Drugs & Pharmacology Authors: Palumbo A, Lau G, Saraceni M Tags: Ann Pharmacother Source Type: research